Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Perampanel - Eisai

Drug Profile

Perampanel - Eisai

Alternative Names: E-2007; ER-155055-90; Fycompa

Latest Information Update: 01 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eisai Co Ltd
  • Developer Eisai Co Ltd; ESTEVE
  • Class Analgesics; Antiepileptic drugs; Nitriles; Pyridines; Pyridones; Small molecules
  • Mechanism of Action AMPA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Partial epilepsies; Tonic-clonic epilepsy
  • Phase III Seizures
  • Phase II Epilepsy
  • Discontinued Migraine; Multiple sclerosis; Neuropathic pain; Parkinson's disease

Most Recent Events

  • 15 Oct 2019 Registered for Partial epilepsies (Adjunctive treatment, In adolescents, In adults, In children, In the elderly) in China (PO)
  • 25 Jun 2019 Updated efficacy and safety data from the phase III FREEDOM trial in Partial epilepsies released by Eisai
  • 31 May 2019 Phase-II clinical trials in Epilepsy (Adjunctive treatment, In adolescents, In children, In infants) in Denmark (PO) (NCT04015141) (EudraCT2018-004456-38)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top